Kaer Biotherapeutics

Kaer Biotherapeutics is a private, pre-revenue biotech platform company pioneering high-performance aerosol delivery systems for respiratory medicine. Its core innovation lies in generating high-concentration, respirable aerosols from viscous liquids and complex biologics like antibodies and mRNA, while maintaining payload integrity, at rates up to 10x faster than conventional nebulizers. The company targets acute respiratory care in hospital settings and has expanded its technology into industrial automation and animal health vaccination. Led by founder and CEO Donovan Yeates, PhD, Kaer holds a significant international patent portfolio with 22 issued and 5 pending patents.

Proprietary aerosol generation systems (AeroPulsR for aqueous, SUPRAER for dry) that enable single-pass, high-rate delivery of high-concentration aerosols from complex biologics and viscous formulations while maintaining payload integrity.

Kaer competes with established nebulizer companies (e.g., Philips, Vectura) and specialized drug delivery firms. Its key differentiator is the ability to aerosolize viscous, complex biologics at high speeds without degradation, a niche with limited direct competition but high technological barriers.